<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01503775</url>
  </required_header>
  <id_info>
    <org_study_id>NV-PMK-0902</org_study_id>
    <nct_id>NCT01503775</nct_id>
  </id_info>
  <brief_title>TRUfill®'s Line in Intracranial aNeurysm Embolisation</brief_title>
  <acronym>TRULINE</acronym>
  <official_title>A Prospective, Multicentric Observational Study Evaluating the Long Term Efficacy and Safety of the CODMAN TRUFILL®'s Line of Coils in the Endovascular Treatment of Intracranial Aneurysms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Codman &amp; Shurtleff</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Codman &amp; Shurtleff</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the long term efficacy and safety of the CODMAN
      TRUFILL®'s line of coils in the treatment of patients with intracranial ruptured or
      non-ruptured aneurysms in real-life routine clinical practice.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2011</start_date>
  <completion_date type="Actual">August 1, 2014</completion_date>
  <primary_completion_date type="Actual">August 1, 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The long term safety of the coiling procedure with the CODMAN TRUFILL®'s line of coils will be assessed by the combined morbidity-mortality rate (CMMR) observed during the procedure and up to 1 year post-procedure follow-up.</measure>
    <time_frame>Observed during the procedure and up to 1 year post-procedure follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The procedural CMMR observed during the procedure and up to 30 Days post procedure follow-up.</measure>
    <time_frame>Observed during the procedure and up to 30 Days post procedure follow-up.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of permanent morbidity and mortality observed at 30 Days and at 1 year post-procedure follow-up, defined as a mRS of 3 to 6.</measure>
    <time_frame>Observed at 30 Days and at 1 year post-procedure follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of absence of deterioration or improvement of the neurological status observed at 30 days and at 1 year post procedure follow-up</measure>
    <time_frame>Observed at 30 days and at 1 year post procedure follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The overall rate of Adverse Event/Serious Adverse Event observed during the procedure, at 30 days and up to 1 year post-procedure follow-up</measure>
    <time_frame>Observed during the procedure, at 30 days and up to 1 year post-procedure follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of Adverse Event/Serious Adverse Event related to the device and/or to the procedure observed during the procedure, at 30 days and up to 1 year post-procedure follow-up</measure>
    <time_frame>Observed during the procedure, at 30 days and up to 1 year post-procedure follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of Unanticipated Adverse Device Effects observed during the procedure, at 30 days and up to 1 year post-procedure follow-up</measure>
    <time_frame>Observed during the procedure, at 30 days and up to 1 year post-procedure follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of per-procedural subarachnoid hemorrhage of the treated aneurysm and rate of per-procedural SAH leading to a modification of the procedure initially planned</measure>
    <time_frame>During the procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of recurrent subarachnoid hemorrhage of the treated aneurysm at one-year post-procedure follow-up</measure>
    <time_frame>1 year post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of aneurysm occlusion at the end of the procedure and at 1 year post-procedure follow-up</measure>
    <time_frame>End of the procedure and at 1 year post-procedure follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of aneurysm recanalisation up to 1 year post-treatment defined as any increase in the size of the remnant or defined as a change of classification of the Raymond scale result related up to the 1 year post-procedure follow-up</measure>
    <time_frame>Up to 1 year post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of spontaneous aneurysm regression up to 1 year post-treatment defined as any decrease in the size of the remnant or defined as a change of classification of the Raymond scale result related up to the 1 year post-procedure follow-up</measure>
    <time_frame>Up to the 1 year post-procedure follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of retreatment at 1 year follow-up representing the rate of major recurrence on the target aneurysm observed up to the 1 year post-procedure follow-up</measure>
    <time_frame>Up to the 1 year post-procedure follow-up</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">171</enrollment>
  <condition>Aneurysms</condition>
  <arm_group>
    <arm_group_label>TRUFILL® DCS Orbit Galaxy</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Routine clinical practice
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient ≥ 18 years old

          -  Patient presenting one or more ruptured or non-ruptured intracranial aneurysms
             assessed by angiography

          -  Patient implanted with one or more CODMAN TRUFILL® coils

          -  Patient agree to take part in the study, or agreement of a representative of the
             patient in case of patient inability, after being informed by the investigator and
             have received information letter.

        Exclusion Criteria:

          -  Patient who does not accept to take part in the study after being informed

          -  Patient already enrolled in a clinical trial involving experimental medication or
             device.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopitaux Civils de Colmar</name>
      <address>
        <city>Colmar</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Neurologique</name>
      <address>
        <city>Lyon</city>
        <zip>69394</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Clairval</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Adullte La Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondation Rothschild</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2011</study_first_submitted>
  <study_first_submitted_qc>December 31, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2012</study_first_posted>
  <last_update_submitted>June 19, 2017</last_update_submitted>
  <last_update_submitted_qc>June 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>intracranial</keyword>
  <keyword>ruptured</keyword>
  <keyword>non-ruptured</keyword>
  <keyword>aneurysms</keyword>
  <keyword>Intracranial ruptured or non-ruptured aneurysms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Intracranial Aneurysm</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

